Recently, the nation's first autologous NK cell adjuvant therapy technology covering eight types of tumor indications was officially approved for clinical application at West China Lecheng Hospital.

The cost of a single treatment session is 49,800 yuan, with a total of 6 sessions per course, and the total cost for the entire course is approximately 298,800 yuan. This treatment covers lung cancer, breast cancer, stomach cancer, pancreatic cancer, ovarian cancer, liver cancer, prostate cancer, and colorectal cancer.

According to a January 28 report from the Boao Lecheng International Medical Tourism Pilot Zone Administration, with the recent approval of four new cell and gene therapy (CGT) projects, Lecheng has now achieved a total of 20 CGT projects that have been translated into clinical applications.

Recent additions include:

Shulan (Boao) Hospital: Autologous NK Cell Therapy Project

Ciming Boao International Hospital: Umbilical cord mesenchymal stem cell therapy for type 2 diabetes (for patients whose blood sugar is still poorly controlled after using at least three hypoglycemic drugs in combination) .

Ruijin Hainan Hospital: KSD-101 Dendritic Cell (DC) Drug (for the treatment of EBV-related hematologic malignancies, from Hengsai Biotechnology)

Boao Super Hospital: German DC Immunotherapy Technology

Previously, 15 CGT projects had been launched in Boao Lecheng.

Currently, the Lecheng Administration has issued a notice soliciting applications for the third batch of biomedical new technology transformation and application projects, with the application deadline being March 9, 2026.